| 5.61 0.74 (15.2%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.72  |
1-year : | 7.85 |
| Resists | First : | 5.75 |
Second : | 6.72 |
| Pivot price | 4.53 |
|||
| Supports | First : | 4.46 |
Second : | 3.67 |
| MAs | MA(5) : | 4.91 |
MA(20) : | 4.45 |
| MA(100) : | 4.07 |
MA(250) : | 4.77 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 85.2 |
D(3) : | 84.2  |
| RSI | RSI(14): 75.7 |
|||
| 52-week | High : | 7.94 | Low : | 2.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TLSI ] has closed Bollinger Bands are 16.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.95 - 4.97 | 4.97 - 5 |
| Low: | 4.55 - 4.58 | 4.58 - 4.62 |
| Close: | 4.82 - 4.87 | 4.87 - 4.92 |
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Fri, 07 Aug 2026
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - simplywall.st
Fri, 07 Aug 2026
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
Fri, 07 Aug 2026
TriSalus Life Sciences Q2 Earnings Call Highlights - tradingview.com
Fri, 07 Aug 2026
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Thu, 06 Aug 2026
Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance - Stock Titan
Thu, 06 Aug 2026
TriSalus Life Sciences Reports Second Quarter 2026 Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 61 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 34 (%) |
| Held by Institutions | 34.6 (%) |
| Shares Short | 3,560 (K) |
| Shares Short P.Month | 2,190 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | -60.9 % |
| Operating Margin | -94.6 % |
| Return on Assets (ttm) | -35.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -3 % |
| Gross Profit (p.s.) | 0.62 |
| Sales Per Share | 0.73 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -3.96 |
| PEG Ratio | 0 |
| Price to Book value | 26.71 |
| Price to Sales | 7.67 |
| Price to Cash Flow | -17.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|